TABLE 2.
Characteristics of patients in each histocluster
| Patients in cluster A (n = 25) | Patients in cluster B (n = 38) | p | |
|---|---|---|---|
| Age, median (range) | 11.5 (3–18) | 13.6 (3–24) | 0.62 |
| Sex: female, n (%) | 14 (56) | 18 (47) | 0.61 |
| Diagnosis, n (%) | |||
| AIH | 18 (72) | 14 (37) | 0.03 |
| PSC | 4 (16) | 15 (39) | |
| ASC | 3 (12) | 9 (24) | |
| IBD, n (%) | 9 (36) | 19 (50) | 0.31 |
| Liver function at BL, median (range) | |||
| INR | 1.17 (0.84–3.69) | 1.12 (0.9–1.92) | 0.34 |
| Total bilirubin (mg/dL) | 0.5 (0.1–26.5) | 0.6 (0.2–14.2) | 0.68 |
| MELD | 10 (6–27) | 8 (6–23) | 0.1 |
| Serum liver biochemistries at BL, median (range; U/L) | |||
| ALT | 186 (17–2687) | 162 (20–2814) | 0.35 |
| AST | 128 (9–2227) | 130 (33–2985) | 0.54 |
| ALP | 276 (46–1009) | 315 (56–1402) | 0.08 |
| GGT | 76 (10–857) | 235 (16–890) | 0.001 |
| IgG at BL, median (range; mg/dL) | 1390 (356–4130) | 1980 (753–5170) | 0.01 |
| Histopathology, median (range) | |||
| METAVIR classification | 2 (0–3) | 2.5 (1–4) | 0.006 |
| Ishak stage | 2 (0–4) | 4 (0–6) | 0.005 |
| HAI score | 4 (0–18) | 7 (0–14) | 0.65 |
| Serum liver biochemistries at 12 months, median (range; U/L) n = 57 | |||
| ALT | 31 (14–161) | 44 (6–330) | 0.16 |
| Abnormal ALT (n, %) | 2 (9) | 13 (38) | 0.02 |
| AST | 30 (13–89) | 41 (11–164) | 0.14 |
| Abnormal AST (n, %) | 8 (35) | 20 (59) | 0.1 |
| ALP | 172 (49–478) | 202 (36–923) | 0.48 |
| Abnormal ALP (n, %) | 3 (13) | 7 (21) | 0.72 |
| GGT | 17 (5–228) | 38 (7–1364) | 0.04 |
| Abnormal GGT (n, %) | 6 (26) | 14 (41) | 0.27 |
| Any liver complication, n (%) | 5 (20) | 12 (32) | 0.39 |
| Liver transplant, n (%) | 1 (4) | 5 (13) | 0.39 |
Abbreviations: AIH, autoimmune hepatitis; ASC, autoimmune sclerosing cholangitis; BL, baseline; HAI, Histologic Activity Index; IBD, inflammatory bowel disease; IgG, immunoglobulin G; INR, international normalized ratio; PSC, primary sclerosing cholangitis.
Bold values are Statistical significance of p value.